Oppenheimer Reiterates Corbus (CRBP) at Outperform, 'could weigh positively for CRBP with CRB-913's substantially lower CNS penetration'
Tweet Send to a Friend
Oppenheimer analyst Jeff Jones reiterated an Outperform rating and $88.00 price target on Corbus Pharmaceuticals (NASDAQ: CRBP).The analyst commented: "The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
